Solid biosciences announces organizational changes to prioritize development of sgt-001

Cambridge, mass., jan. 09, 2020 (globe newswire) -- solid biosciences inc. (nasdaq: sldb) today announced changes to its organizational structure to create a leaner company focused on advancing sgt-001, a gene transfer candidate for the treatment of duchenne muscular dystrophy (duchenne). in december 2019, the company reported biomarker data from two patients that provide evidence that sgt-001 is biologically active with differentiated properties which solid believes warrants further evaluation.
SLDB Ratings Summary
SLDB Quant Ranking